Australia (AU)

The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates (2021) Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E Journal article Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability (2021) Burnett DL, Jackson KJ, Langley DB, Aggrawal A, Stella AO, Johansen MD, Balachandran H, et al. Journal article Mesoporous Bioactive Glasses in Cancer Diagnosis and Therapy: Stimuli-Responsive, Toxicity, Immunogenicity, and Clinical Translation (2021) Sharifi E, Bigham A, Yousefiasl S, Trovato M, Ghomi M, Esmaeili Y, Samadi P, et al. Journal article, Review article Three-Dimensional Placement and Transmit Power Design for UAV Covert Communications (2021) Zhou X, Yan S, Ng DWK, Schober R Journal article Correction to: Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases (Modern Pathology, (2021), 10.1038/s41379-021-00923-6) (2021) Farcaş M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R, Williamson SR, et al. Journal article, Erratum ENETS consensus guidelines for synoptic reporting of radiology studies (2021) Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, De Herder WW, Pavel ME, et al. Journal article Resource Allocation for Large IRS-Assisted SWIPT Systems with Non-linear Energy Harvesting Model (2021) Xu D, Yu X, Jamali Kooshkghazi V, Ng DWK, Schober R Conference contribution The meta-analyses of deliberate practice underestimate the effect size because they neglect the core characteristic of individualization—an analysis and empirical evidence (2021) Debatin T, Hopp M, Vialle W, Ziegler A Journal article Emerging technologies in paediatric laboratory medicine (2021) Mak C, Papassotiriou I, Zierk J, Kohse KP, Greaves RF, Geaghan SM, Lang T, Loh TP Journal article, Review article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution